A Call for Updates to Hormone Therapy Guidelines for Gender-Diverse Adults Assigned Male at Birth.

Reema Patel, Stanley Korenman, Amy Weimer, Shira Grock

Abstract readEditorial

In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Feminizing Hormone Therapy in the Male Spontaneous Hypertensive Rat Impairs Accuracy of Estimated Renal Filtration.Journal of the Endocrine Society · 2025
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Reema PatelEndocrinology, Diabetes and Metabolism, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, USA.

Stanley KorenmanEndocrinology, Diabetes and Metabolism, University of California Los Angeles David Geffen School of Medicine, Los Angeles, USA.

Amy WeimerGeneral Internal Medicine, University of California Los Angeles David Geffen School of Medicine, Los Angeles, USA.

Shira GrockEndocrinology, Diabetes and Metabolism, University of California Los Angeles David Geffen School of Medicine, Los Angeles, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gender-affirming hormone therapy for assigned male at birth (AMAB) individuals with gender incongruence typically consists of estradiol with or without an anti-androgen to achieve physical changes and psychological benefits. However, prescribed hormone regimens vary considerably, and high-quality research in this area is extremely limited. Additional evidence-based research evaluating patient-reported outcome measures (PROMs) is needed to fill current knowledge gaps and create a personalized therapeutic approach for AMAB individuals. This editorial provides a critical description of current treatment options, discusses their variability, reviews some discrepancies in guideline-based dosing recommendations, and recommends areas for further study.

Indexed as

anti-androgenestradiolgender incongruencehormone therapytransgender

Identifiers

PMID39006737

DOI10.7759/cureus.62262

PMCPMC11245323

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.